

References for Module 5

- Adab, N. (2006). Birth defects and epilepsy medication. *Expert review of neurotherapeutics*, 6(6), 833-845.
- Antonuccio, D.O., Danton, W.G., & DeNelsky, G.Y., Greenberg, R.P., & Gordon, J.S. (1999). Raising questions about antidepressants. *Psychotherapy and Psychosomatics*, 68, 3-14.
- Aparasu, R., Bhatara, V., & Gupta, S. (2005). U.S. national trends in the use of antipsychotic during office visits, 1998-2002. *Annals of Clinical Psychiatry*, 17(3), 147-152.
- APA reports cites critical gaps in evidence for current treatment of children's behavioral and mental health problems. (2006). Retrieved March 28, 2007 from, http://www.apa.org/releases/children_meds.html
- APA Working Group on Psychoactive Medications for Children and Adolescents (2006). *Report of the Working Group on Psychoactive Medications for Children and Adolescents. Psychopharmacological, psychosocial, and combined interventions for childhood disorders: Evidence base, contextual factors, and future directions.* Washington, DC: American Psychological Association. Retrieved on October 23, 2007 from <http://www.apa.org/pi/cyf/childmeds.pdf>
- Berenson, A. (2008, January 31). Lilly considers \$1 billion fine to settle case. *The New York Times*. Retrieved from <http://query.nytimes.com/gst/fullpage.html?res=9B03E4DE133EF932A05752C0A96E9C8B63>
- Bezchlibnyk-Butler, K. A.Z., & Jeffries, J. J. (2005). *Clinical handbook of psychotropic drugs* (15th rev. ed.). Seattle: Hogrefe.
- Breggin, P. (2006). Recent regulatory changes in antidepressant labels: Implications of activation (stimulation) for clinical practice. *Primary Psychiatry*, 13(1), 57-60.
- Breggin, P. R. (1998). Risks and mechanisms of action of stimulants. In *NIH Consensus Development Conference program and abstracts: Diagnosis and treatment of attention-deficit hyperactivity disorder* (pp. 105-120). Rockville, MD: National Institutes of Health.
- Brown, R. T., & Sammons, M. T. (2002). Pediatric psychopharmacology: A review of new developments and recent research. *Professional Psychology: Research and Practice*, 33(2), 135-147.

- Campbell, M., Rapaport, J., & Simpson, G. (1999). Antipsychotics in children and adolescents, *Journal of the American Academy of Child and Adolescent Psychiatry*, 38(5), 537-545.
- Carey, B. (2007, September 3). More children treated for bipolar disorder. *The New York Times*. Retrieved from http://www.nytimes.com/2007/09/04/health/04psych.html?_r=2&adxnml=1&oref=slogin&adxnmlx=1188923032-vieIaZfSAyw2C//wX2LPCA&oref=slogin
- Carey, B. (2007, September 4). Bipolar illness soars as diagnosis for the young. *The New York Times*. Retrieved from http://www.nytimes.com/2007/09/04/health/04psych.html?_r=1&adxnml=1&oref=slogin&adxnmlx=1188923032-vieIaZfSAyw2C//wX2LPCA
- Cooper, W.O., Arbogast, P.G., Ding, H., Hisckson, G.B., Fuchs, C., & Ray, W.A. (2006). Trends in prescribing antipsychotic medications for U.S. children. *Ambulatory Pediatrics*, 6(2), 79-83.
- Correll, C., & Carlson, H. (2006). Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents, *Journal of the American Academy of Child and Adolescent Psychiatry*, 45(7), 771-791.
- Findling, R., Gracious, B., & Seman, C. (2004). Elevated thyrotropin in bipolar youths prescribed both Lithium and Divalproex Sodium, *Journal of the American Academy of Child and Adolescent Psychiatry*, 43(2), 215-220.
- Golden, A. S., Haut, S. R., & Moshe, S. L. (2006). Nonepileptic uses of antiepileptic drugs in children and adolescents. *Pediatric Neurology*, 34(6), 421-432.
- Gonzalez-Heydrich, J., Raches, D., Wilens, T., Leichtner, A., & Mezzacappa, E. (2003). Retrospective study of hepatic enzyme elevations in children treated with olanzapine, divalproex, and their combination, *Journal of the American Academy of Child and Adolescent Psychiatry*, 42(10), 1227-1233.
- Hammad, , T.A., Laughren, T., Racoosin, J. (2006). Suicidality in pediatric patients treated with antidepressant drugs. *Archives of General Psychiatry*, 63, 332-339.
- Harris, G. (2006, August 21). FDA strengthens warnings on stimulants. *The New York Times*. Retrieved December 4, 2007 from http://www.nytimes.com/2006/08/22/health/policy/22fda.html?_r=1&n=Top/Reference/Times%20Topics/People/H/Harris,%20Gardiner&oref=slogin

- Healy, D. (2003). Lines of evidence on the risks of suicide with selective serotonin reuptake inhibitors. *Psychotherapy and Psychosomatics*, 72(2), 71-79.
- Heres, S., Davis, J., Marino, K., Jetzinger, E., Kissling, W., & Leucht, S. (2006). Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: An exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. *American Journal of Psychiatry*, 163(2), 185-194.
- Jensen, P.S., Arnold, L.E., Swanson, J.M., Vitiello, B., Abikoff, H.B., et al. (2007). 3-year follow-up of the NIMH MTA study. *Journal of the American Academy of Child and Adolescent Psychiatry*, 46(8), 989-1002.
- Kesselheim, A., & Avorn, J. (2007). The role of litigation in defining drug risks, *Journal of the American Medical Association*, 297(3), 308-311.
- Kirsch, I., Moore, T.J., Scoboria, A., & Nicholls, S.S. (2002). The emperor's new drugs: An analysis of antidepressant medication data submitted to the U.S. Food and Drug Administration. *Prevention & Treatment*, 5 (1). Retrieved December 4, 2007 from <http://psycnet.apa.org/index.cfm?fa=search.displayRecord&uid=2002-14079-003>
- Kirsch, I., & Sapirstein, G. (1998, June 26). Listening to Prozac but hearing placebo: A meta-analysis of antidepressant medication. *Prevention & Treatment*, 1(2). Retrieved December 4, 2007 from <http://journals.apa.org/prevention/volume1/pre0010002a.html>
- Kowatch, R., Fristad, M., Birmaher, B., Wagner, K., Findling, R., et al. (2005). Treatment guidelines for children and adolescents with bipolar disorder: Child psychiatric workgroup on bipolar disorder, *Journal of the American Academy of Child and Adolescent Psychiatry*, 44(3), 213-235.
- Kowatch, R., Suppes, T., Carmody, R., Bucci, J., Hume, J., et al. (2000). Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder, *Journal of the American Academy of Child and Adolescent Psychiatry*, 39(6), 713-720.
- Laughren, T.P. (2004, January 5). Background comments for February 2, 2004 Meeting of Psychopharmacological Drugs Advisory Committee (PDAC) and Pediatric Subcommittee of the Antiinfective Drugs Advisory Committee (Peds AC). Memorandum: Department of Health and Human Services Public

- Health Service, Food and Drug Administration, Center for Drug Evaluation and Research.
- Lieberman, J.A., Stroup, T.S., McEvoy, J.P., Swartz, M.S., Rosenbeck, R.A., Perkins, D.O. et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. *The New England Journal of Medicine*, 353(12), 1209-1223.
- Lindenmayer, J., Czober, P., Volavka, J., Citrome, L., Sheitman, B., et al. (2003). Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics, *American Journal of Psychiatry*, 160(2), 290-296.
- Lopez-Larson, M., & Frazier, J.A. (2006). Empirical evidence for the use of lithium and anticonvulsants in children with psychiatric disorders. *Harvard Review of Psychiatry*, 14(6), 285-304.
- Lyons, J., MacIntyre, J., Lee, M., Carpinello, S., Zuber, M., & Fazio, M. (2004). Psychotropic medications prescribing patterns for children and adolescents in New York's public mental health system, *Community Mental Health Journal*, 40(2), 101-118.
- McConville, B. J., & Sorter, M. T. (2004). Treatment challenges and safety considerations for antipsychotic use in children and adolescents with psychoses. *Journal of Clinical Psychiatry*, 65(Suppl6), 20-29.
- McDonagh, M.S., Peterson, K., & Carson, S. (2006). *Drug class review on atypical antipsychotic drugs*. Center for Evidence-based Policy, Oregon Health & Science University. Update #1 Final Report. Retrieved from <http://www.ohsu.edu/drugeffectiveness>
- Medco Health Solutions (2004, May 18). Medco study reveals pediatric spending spike on drugs to treat behavioral problems. Retrieved December 4, 2007, from http://www.drugtrendreport.com/art/drug_trend/dt_symposium_highlights_0517.pdf
- Meyer, J. (2001). Novel antipsychotics and severe hyperlipidemia, *Journal of Clinical Psychopharmacology*, 21(4), 369-374.
- Moncreiff, J., Wessely, S., Hardy, R. (2004). Active placebo versus antidepressants for depression. *Cochrane Data Base of Systematic Reviews*, Issue 1, Art no.: CD003012. DOI: 10.1002/14651858.CD003012.pub.2.

- Moore, T.J., Cohen, M.R., & Furberg, C.D. (2007). Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. *Archives of Internal Medicine*, 167(16), 1752-1759.
- Moreno, C., Laje, G., Blanco, C., Jian, H., Schmidt, A.B., & Olfson, M. (2007). National trends in the outpatient diagnosis and treatment of bipolar disorder in youth. *Archives of General Psychiatry*, 64(9), 1032-1039.
- MTA Cooperative Group (2004). 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder (ADHD): The NIMH MTA follow-up. *Pediatrics*, 113, April, 754-761.
- National Institute of Mental Health. (2000). *Child and Adolescent Bipolar Disorder: An update from the NIMH* (NIH Publication Number: NIH00-4778). Retrieved March 26, 2007, from <http://www.nimh.nih.gov/publicat/index.cfm>
- Olfson, M., Marcus, S.C., Weissman, M.M., & Jensen, P.S. (2002). National trends in the use of psychotropic medications by children. *Journal of the American Academy of Child and Adolescent Psychiatry*, 41(5), 514-21.
- Olfson, M., Blanco, C., Liu, L., Moreno, C., & Laje, G. (2006). National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. *Archives of General Psychiatry*, 63(6), 679-685.
- Pappadopulos, E., Guelzow, T., Wong, C., Ortega, M., & Jensen, P. (2004). A review of the growing evidence base for pediatric psychopharmacology, *Child and Adolescent Psychiatric Clinics of North America*, 13, 817-855.
- Patel, N.C., Crismon, M.L., Hoagwood, K., & Jensen, P.S. (2005). Unanswered questions regarding antipsychotic use in aggressive children and adolescents. *Journal of Adolescent and Child Psychopharmacology*, 15(2), 270-284.
- Preda, A., MacLean, R.W., Mazure, C.M., & Bowers, M.B. (2001). Antidepressant-associated mania and psychosis resulting in psychiatric admissions. *Journal of Clinical Psychiatry*, 62, 30-33.
- Pringle, E. (2007). *Makers of Zyprexa, Risperdal and Seroquel under fire*, Retrieved March, 28, 2007, from <http://www.lawyersandsettlements.com/articles/00660/zyprexa-medical-costs.html>
- Riddle, M.A., Kastelic, E.A. & Frosch, E. (2001). Pediatric psychopharmacology. *Journal of Child Psychology & Psychiatry*, 42(1), 73-90.

- Rush, A.J., Trivedi, M.H., Wisniewski, S.R., Nierenberg, A.A., Stewart, J.W., Warden, D., et al. (2006b). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. *American Journal of Psychiatry*, 163, 1905-1917.
- Ryan, N., Bhatara, V., & Perel, J. (1999). Mood stabilizers in children and adolescents, *Journal of the American Academy of Child and Adolescent Psychiatry*, 38(5), 529-536.
- Schatzberg, A. F., Blier, P., Delgado, P. L., Fava, M., Haddad, P. M., & Shelton, R. C. (2006). Antidepressant discontinuation syndrome: Consensus panel recommendations for clinical management and additional research. *Journal of Clinical Psychiatry*, 67 (suppl 4), 27-30.
- Scheffler, R.M., Hinshaw, S.P., Modrek, S. & Levine, P. (2007). Trends: the global market for ADHD medications. *Health Affairs*, 26(2), 450.
- Silva, R., Munoz, D., Alpert, M., Perlmutter, I., & Diaz, J. (1999). Neuroleptic malignant syndrome in children and adolescents, *Journal of the American Academy of Child and Adolescent Psychiatry*, 38(2), 187-194.
- Stone, M., & Jones, M. L. (2006, November 17). *Clinical review: Relationship between antidepressant drugs and suicidality in adults*. Rockville, MD: Food and Drug Administration.
- Swanson, J., Greenhill, L., Wigal, L. Kollins, S., Stehli, A., Davies, M. et al. (2006). Stimulant-related reductions of growth rates in the PATS. *Journal of the American Academy of Child and Adolescent Psychiatry*, 45(11), 1304-1313.
- Thase, M.E., & Jindal, R.D. (2004). Combining psychotherapy and psychopharmacology for treatment of mental disorders. In M.J. Lambert (Ed.), *Bergin and Garfield's handbook of psychotherapy and behavior change* (5th ed.) (pp. 743-766). New York: Wiley.
- Trivedi, M.H., Fava, M., Wisniewski, S.R., Thase, M.E., Quitkin, F., Warden, D. et al (2006b). Medication augmentation after the failure of SSRIs for depression. *New England Journal of Medicine*, 354, 1243-1252.
- Tyrer, P., Oliver-Africano, P.C., Ahmed, Z., Bouras, N., Cooray, S., et al. (2008). Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: A randomized controlled trial. *The Lancet*, 371(9606), 57-63.

Wakefield, J.C., Schmitz, M.F., First, M.B. & Horwitz, A.V. (2007). Extending the Bereavement Exclusion for Major Depression to Other Losses: Evidence From the National Comorbidity Survey. *Archives of General Psychiatry*, 64:433-440.

Waters, R. (2007, September 17). Hyperactivity drugs to be studied for heart risk. Bloomberg. Retrieved from <http://www.bloomberg.com/apps/news?pid=newsarchive&sid=a5ap6JbK5NDA#>